Knee Bursitis Global Market Report 2024

Knee bursitis occurs when one or more of the small, fluid-filled sacs near the knee joint become inflamed. These sacs, called bursae, cushion and reduce friction between tissues such as bones, tendons, and muscles. Inflammation of these bursae leads to symptoms such as pain, swelling, and limited movement in the knee.

Diagnosis of knee bursitis typically involves imaging tests such as ultrasound or MRI scans. These tests help visualize inflammation and fluid buildup in the bursae surrounding the knee joint. Treatment options include medication and, in some cases, surgery. These treatments are utilized by hospitals, clinics, diagnostic centers, research institutions, academic establishments, and others.

The knee bursitis research report is one of a series of new reports that provides knee bursitis market statistics, including the knee bursitis industry's global market size, regional shares, competitors with a knee bursitis market share, detailed knee bursitis market segments, market trends and opportunities, and any further data you may need to thrive in the knee bursitis industry. This knee bursitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The knee bursitis market size has grown strongly in recent years. It will grow from $2.48 billion in 2023 to $2.66 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. During the historic period, growth can be attributed to factors such as an aging population, increased engagement in sports and physical activities, enhanced diagnostic techniques, improved healthcare access, and educational initiatives targeting healthcare professionals and patients.

The knee bursitis market size is expected to see strong growth in the next few years. It will grow to $3.54 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The growth is anticipated due to heightened awareness initiatives focused on prevention and management, augmented disposable incomes, escalating healthcare expenditures, and greater awareness and diagnosis of knee bursitis. Key trends in the forecast period encompass advancements in diagnostic methods, the emergence of innovative therapies, progress in research and development endeavors, as well as the adoption of telemedicine and remote monitoring technologies.

The growing prevalence of bone-related diseases, such as osteoporosis, arthritis, and bone cancer, is expected to drive the expansion of the knee bursitis market in the future. These diseases affect the skeletal system's structure, strength, and functionality, and are increasingly prevalent due to factors such as aging populations, sedentary lifestyles, poor nutrition, and environmental changes. Conditions such as osteoarthritis and rheumatoid arthritis can lead to knee bursitis by causing inflammation and excessive pressure on the knee bursa, resulting in pain, swelling, and reduced joint function. For example, Healthy Bones Australia projected in September 2022 that Australia would have 6.2 million individuals aged 50 and above suffering from osteoporosis or osteopenia in 2022, highlighting the significant impact of poor bone health on knee-related conditions. Therefore, the rising prevalence of bone-related diseases is a key driver of growth in the knee bursitis market.

The anticipated growth of the knee bursitis market is expected to be driven by the increasing diabetic population in the coming years. Diabetes, a chronic condition characterized by the body's inability to regulate blood sugar levels effectively, results from insufficient insulin production or ineffective insulin use. Factors contributing to the rise in diabetes cases include sedentary lifestyles, unhealthy dietary habits, and genetic predispositions. Diabetic individuals are at higher risk of developing knee bursitis due to inflammation caused by prolonged pressure on the knees, impaired immune function, or complications related to diabetes. For instance, a July 2021 report by the International Diabetes Federation projected a substantial increase in the global diabetic population, estimating 643 million people living with diabetes by 2030 and 783 million by 2045. Therefore, the expanding diabetic population is a key driver behind the expected growth of the knee bursitis market.

The growth of the knee bursitis market is expected to be driven by the increasing geriatric population in the years ahead. The geriatric population, typically defined as individuals aged 65 years and older, faces specific health challenges associated with aging. Advances in healthcare have contributed to longer life expectancies globally while declining birth rates in many regions have further contributed to the aging demographic trend. Among the health issues commonly experienced by older adults is knee bursitis, which results from wear and tear on the joints, leading to inflammation of the bursae sacs surrounding the knee joint. For example, the World Health Organization projected in October 2022 that the global population aged 60 years and over will grow significantly, from 1 billion in 2020 to 1.4 billion by 2030, reaching 2.1 billion by 2050. Moreover, the number of individuals aged 80 years and older is expected to triple, reaching 426 million by 2050. This demographic shift underscores the increasing prevalence of knee bursitis among older adults, driven by age-related joint issues. Therefore, the expanding geriatric population is a pivotal factor propelling the growth of the knee bursitis market as healthcare systems adapt to meet the needs of an aging population facing joint-related challenges.

Major companies operating in the knee bursitis market are Pfizer Inc., Merck & Co. Inc, Bayer AG, Novartis AG, Roche Holding AG, Medtronic plc, Eli Lilly and Company, Amgen Inc, Gilead Sciences Inc., Stryker Corporation, Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Zimmer Biomet Holdings Inc., DePuy Synthes Inc., Arthrex Inc., Globus Medical Inc., Bioventus LLC, Exactech Inc., Genentech Inc., Conformis Inc., Oncolys BioPharma Inc, Bellicum Pharmaceuticals Inc, Merrimack Pharmaceuticals Inc, 4Med Medical Solutions Inc.

North America was the largest region in the knee bursitis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the knee bursitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the knee bursitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The knee bursitis market consists of revenues earned by entities by providing services such as medical consultation, medication management, surgical intervention, and rehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The knee bursitis market also includes sales of knee braces and supports, cold packs and heat wraps, anti-inflammatory medications, and corticosteroid injections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.